Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549
Jingting Min, Chirong Long, Lu Zhang, et al.
Bioengineered (2022) Vol. 13, Iss. 4, pp. 9232-9248
Open Access | Times Cited: 23

Showing 23 citing articles:

Advances and challenges in the treatment of lung cancer
Yuting Li, Bingshuo Yan, Shiming He
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115891-115891
Open Access | Times Cited: 153
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma
Payal D. Shah, Alexander C. Huang, Xiaowei Xu, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 5, pp. 821-829
Open Access | Times Cited: 54
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 47
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, et al.
Oncology Letters (2022) Vol. 24, Iss. 5
Open Access | Times Cited: 41
Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer
Parham Jabbarzadeh Kaboli, Hsiao‐Fan Chen, Ali Babaeizad, et al.
Cancer Letters (2024) Vol. 588, pp. 216780-216780
Closed Access | Times Cited: 16
MET Activation in Lung Cancer and Response to Targeted Therapies
Sarah Anna Okun, Daniel Lu, Katherine Sew, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 281-281
Open Access | Times Cited: 1
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment
Shuxi Yao, Xinyue Liu, Yanqi Feng, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9101-9101
Open Access | Times Cited: 5
Targeted therapy for rare lung cancers: Status, challenges, and prospects
Chunsen Wang, Xiang Yuan, Jianxin Xue
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1960-1978
Open Access | Times Cited: 10
Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor
HuanRan Yang, Yanjun Zhang, YanQiu Li, et al.
Technology in Cancer Research & Treatment (2025) Vol. 24
Open Access
Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer
Lisha Ye, Wenjing Wang, Huihui Li, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
Cristina Chiriaco, Chiara Donini, Marco Cortese, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 12
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives
John Maher
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 515-532
Open Access | Times Cited: 7
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Abdolreza Esmaeilzadeh, Kaveh Hadiloo, Marjan Jabbari, et al.
Life Sciences (2023) Vol. 337, pp. 122381-122381
Closed Access | Times Cited: 7
Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants
Fei Gao, Xiaoqing You, Liu Yang, et al.
International Reviews of Immunology (2024) Vol. 43, Iss. 5, pp. 280-308
Closed Access | Times Cited: 1
Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach
O. Bar, Angel Porgador, Tomer Cooks
Journal of Extracellular Biology (2024) Vol. 3, Iss. 9
Open Access | Times Cited: 1
Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics
Lingyu Hu, Xiaoguang Wang, Zhengwei Song, et al.
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 1
HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met
Haiyan Ma, Wenwen Wei, Dandan Liang, et al.
Immunological Investigations (2023) Vol. 52, Iss. 6, pp. 735-748
Open Access | Times Cited: 3
The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer
Shuangcui Wang, Guan Zhang, Qian Cui, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 11
Open Access | Times Cited: 3
DC-T cell axis is an effective target for treating non-small cell lung cancer
Shuangcui Wang, Guan Zhang, Qian Cui, et al.
Authorea (Authorea) (2024)
Open Access
Lung cancer immunotherapy: Status quo, problems, and prospects
I.V. Ozerskaya Ozerskaya, Gaukhar M. Yusubalieva, Oksana A. Zhukova, et al.
(2024) Vol. 26, Iss. 4, pp. 87-97
Closed Access
Addressing the unmet need in NSCLC progression with advances in second-line therapeutics
Kaige Wang, Alexis Leyba, Robert Hsu
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 6, pp. 1297-1320
Open Access
Data from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma
Payal D. Shah, Alexander C. Huang, Xiaowei Xu, et al.
(2023)
Open Access
Data from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Payal D. Shah, Alexander C. Huang, Xiaowei Xu, et al.
(2023)
Open Access
Page 1

Scroll to top